| Extensive stage SCLC (Es-SCLC) | ||
| Extensive stage SCLC (Es-SCLC) - maintenance (M) | Extensive stage SCLC (Es-SCLC) - 1st Line (L1) | |
| Immune checkpoint association | ||
| durvalumab plus tremelimumab | ||
| durvalumab plus tremelimumab plus SoC | CASPIAN ... | |
| nivolumab plus ipilimumab | CheckMate 451 ... | |
Study type:
delta: difference in rate or median (if available)
-
About us
-
Contact us
-
Method
-
RSS
Made with
in Lyon
-
Credits
-
Privacy policy
-
